Healthcare provider profile · identity verified

Michael S. Provenghi, MD

Family Practice · ANAHEIM, CA · NPI 1265503239

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	316	112
Losartan Potassium	Losartan Potassium	180	67
Rosuvastatin Calcium	Rosuvastatin Calcium	175	65
Levothyroxine Sodium	Levothyroxine Sodium	147	48
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	116	25
Amlodipine Besylate	Amlodipine Besylate	104	41
Metformin Hcl	Metformin Hcl	101	34
Omeprazole	Omeprazole	101	40
Lisinopril	Lisinopril	99	33
Terazosin Hcl	Terazosin Hcl	90	22
Atenolol	Atenolol	86	23
Gabapentin	Gabapentin	84	28
Glipizide	Glipizide	80	33
Ozempic	Semaglutide	79	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	73	29
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	69	24
Hydrochlorothiazide	Hydrochlorothiazide	65	23
Meloxicam	Meloxicam	65	30
Furosemide	Furosemide	64	27
Potassium Chloride	Potassium Chloride	63	29
Prednisone	Prednisone	60	53
Ibuprofen	Ibuprofen	59	24
Albuterol Sulfate Hfa	Albuterol Sulfate	58	22
Pantoprazole Sodium	Pantoprazole Sodium	54	21
Metformin Hcl Er	Metformin Hcl	52	18
Cephalexin	Cephalexin	49	43
Trazodone Hcl	Trazodone Hcl	48	22
Famotidine	Famotidine	47	19
Alendronate Sodium	Alendronate Sodium	46	17
Lorazepam	Lorazepam	45	suppressed
Topiramate	Topiramate	44	17
Tamsulosin Hcl	Tamsulosin Hcl	43	15
Allopurinol	Allopurinol	39	13
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	33	11
Azithromycin	Azithromycin	32	30
Fluoxetine Hcl	Fluoxetine Hcl	32	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	32	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	31	29
Pradaxa	Dabigatran Etexilate Mesylate	31	suppressed
Sertraline Hcl	Sertraline Hcl	30	14
Jardiance	Empagliflozin	27	11
Wixela Inhub	Fluticasone Propion/Salmeterol	27	suppressed
Finasteride	Finasteride	26	12
Tramadol Hcl	Tramadol Hcl	25	suppressed
Humulin N	Insulin Nph Human Isophane	24	suppressed
Morphine Sulfate Er	Morphine Sulfate	24	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Alprazolam	Alprazolam	23	suppressed
Bupropion Hcl Sr	Bupropion Hcl	23	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	23	23
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	23	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	23	23
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	22	22
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Fluticasone Propionate	Fluticasone Propionate	22	suppressed
Hydrocortisone	Hydrocortisone	22	11
Spironolactone	Spironolactone	21	suppressed
Acyclovir	Acyclovir	18	11
Estradiol	Estradiol	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Duloxetine Hcl	Duloxetine Hcl	15	suppressed
Ondansetron Odt	Ondansetron	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	11
Naltrexone Hcl	Naltrexone Hcl	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	13	13
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Morphine Sulfate	Morphine Sulfate	13	suppressed
Pitavastatin Calcium	Pitavastatin Calcium	13	suppressed
Carvedilol	Carvedilol	12	suppressed
Donepezil Hcl	Donepezil Hcl	12	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Simvastatin	Simvastatin	12	suppressed
Eliquis	Apixaban	11	suppressed
Fluocinonide	Fluocinonide	11	suppressed
Humulin R	Insulin Regular, Human	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error